Who Owns 10X Genomics Company?

10X Genomics Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns 10x Genomics?

Understanding a company's ownership is key to grasping its direction and accountability, especially after significant events like an IPO. 10x Genomics, a life science technology firm, was established in 2012 with a mission to transform biological research through high-resolution insights.

The company offers integrated solutions comprising instruments, consumables, and software designed to analyze biological systems with unparalleled resolution and scale. Their innovative platforms, including the Chromium and Visium, are instrumental in advancing fields like cancer research and immunology, aiding discoveries that were previously out of reach. The company's 10X Genomics BCG Matrix analysis highlights its product portfolio's strategic positioning.

As of July 24, 2025, 10x Genomics boasts a market capitalization of approximately $1.72 billion. This valuation reflects its significant impact and growth since its IPO in September 2019, which successfully raised around $390 million.

10X Genomics was established in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. Their collective aim was to advance genomics technologies, offering deeper insights into biological complexities. Serge Saxonov, the current CEO, previously played a key role at 23andMe. Ben Hindson brought expertise in microfluidics and single-cell genomics, while Kevin Ness contributed experience in high-throughput sequencing before his departure in late 2016. The company's name, '10x,' reflects its ambition for significant impact in the genomics field.

Founding Vision

The founders aimed to overcome limitations in existing genomics tools. Their goal was to provide high-resolution insights into complex biological systems.

Key Founders

Serge Saxonov (CEO) brought experience from 23andMe. Ben Hindson (CSO) specialized in microfluidics and single-cell genomics. Kevin Ness (former CTO) had expertise in high-throughput sequencing.

Company Name Significance

The name '10x' signifies the company's aspiration for exponential advancement. This ambition is central to its mission in the genomics sector.

Early Funding Rounds

Initial funding included a seed round and a Series A in 2013, securing approximately $22 million. A Series B round in 2015 raised $55 million, supporting development.

Total Funding Raised

Across eight funding rounds, the company raised a total of $243 million. The latest Series D in January 2019 brought in $85 million from investors like Fidelity and Wells Fargo.

Legal Affirmation

An arbitration dispute initiated by Bio-Rad in 2014 was resolved in 2015. An arbitrator denied the claims of breach of obligations, affirming the founders' actions.

Founders' Equity and Control

While specific initial equity distributions for the 10X Genomics founders are not publicly disclosed, the early ownership structure featured a multi-class stock system. This system concentrated voting power among the initial stockholders, reflecting the founders' vision and control in the company's formative stages. Understanding this structure is key to grasping the early 10X Genomics ownership dynamics. The company's journey, including its business model, is detailed in an article about the Revenue Streams & Business Model of 10X Genomics.

• Founders: Serge Saxonov, Ben Hindson, Kevin Ness.
• Founding Year: 2012.
• Early Funding: Series A ($22 million in 2013), Series B ($55 million in 2015).
• Total Funding: $243 million across eight rounds.
• Latest Funding: Series D ($85 million in January 2019).
• Key Investors: Fidelity Investments, Wells Fargo, Meritech.
• Legal Resolution: Bio-Rad arbitration denied in 2015.

10X Genomics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

10X Genomics became a publicly traded company on September 12, 2019, through its IPO on the Nasdaq Global Select Market, raising approximately $390 million. The initial offering price was $39.00 per share. As of July 24, 2025, the company's market capitalization stands at approximately $1.72 billion.

The ownership of 10X Genomics is predominantly held by institutional investors, with estimates ranging from approximately 96.93% to 99.74% as of July 2025. Key institutional shareholders include ARK Investment Management LLC, The Vanguard Group, Inc., FMR LLC, UBS Asset Management AG, and BlackRock, Inc. Company insiders, including executives, directors, and co-founders, collectively own about 9.39% of the company's shares as of July 2025, indicating a strong alignment of interests with the company's performance. This public trading status necessitates adherence to SEC regulations, ensuring increased transparency through public filings like Form 10-K and Form 10-Q, which are crucial for understanding the Marketing Strategy of 10X Genomics and its financial health.

Key Ownership Insights

Understanding who owns 10X Genomics is vital for assessing its strategic direction and stability.

• Institutional investors hold the vast majority of 10X Genomics stock.
• Major shareholders include prominent investment firms like ARK Investment Management and The Vanguard Group.
• Insider ownership reflects the commitment of the leadership team.
• The company's transition to a public entity has increased transparency and regulatory oversight.

10X Genomics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of April 2025, the Board of Directors for 10x Genomics is comprised of Serge Saxonov (Co-founder, CEO & Director), Ben Hindson (Co-founder, President, Chief Scientific Officer & Director), and John Stuelpnagel, who serves as the Chairman. The board also includes Kim Popovits, Shehnaaz Suliman, Sri Kosaraju, Alan Mateo, and Sarah Teichmann, reflecting a commitment to independent oversight with the separation of Chairman and CEO roles.

The voting power within 10x Genomics is significantly concentrated due to its dual-class share structure. Class B common stock, held by early stockholders including the co-founders, carries ten votes per share, while Class A common stock has one vote per share. This structure means that Class A stockholders generally have a limited influence on corporate decisions, as evidenced by Class B shares representing approximately 97.7% of the total voting power following the IPO. The board's staggered three-year terms, with only one class up for election annually, further solidifies this control, as stockholders do not have cumulative voting rights, allowing a majority to elect all directors. As of January 31, 2024, the company had 105,109,711 shares of Class A common stock and 14,056,833 shares of Class B common stock outstanding, highlighting the substantial voting advantage held by Class B shareholders.

Understanding 10X Genomics Ownership Structure

The ownership structure of 10x Genomics is characterized by a dual-class share system that grants disproportionate voting power to early investors and founders.

• Class B shares hold 10 votes each, while Class A shares have 1 vote.
• Co-founders Serge Saxonov and Ben Hindson are key figures in the company's leadership and ownership.
• This structure ensures that a small group of early stockholders, including the 10X Genomics founders, maintain significant control over corporate governance.
• Understanding this dynamic is crucial for analyzing 10X Genomics stock and its long-term strategic direction, especially when considering the Competitors Landscape of 10X Genomics.

10X Genomics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent executive appointments and insider trading activity have shaped the ownership landscape of 10x Genomics over the past few years. Key leadership changes, including new Chief Commercial and Financial Officers, alongside board additions, signal a strategic focus on growth and executive strength. These developments occur against a backdrop of fluctuating market capitalization and evolving insider investment patterns.

Insider selling has outpaced buying in the last year, with total insider sales exceeding $4.2 million. Despite this, insiders collectively retain an 8.3% stake in the company as of July 1, 2025, valued at approximately $119 million. The company's market capitalization experienced a significant decrease of 73.72% from January 2024 to December 2024, falling from $6.62 billion to $1.74 billion. However, by July 28, 2025, the market cap had recovered to $1.906 billion, reflecting a 33.68% increase over the preceding 30 days, though it remained down 21.60% year-over-year. Institutional ownership has grown, with 515 institutions holding 135,360,519 shares as of July 28, 2025, indicating sustained interest from investment firms.

Executive Leadership Changes

In August 2024, 10x Genomics appointed new executives, including a Chief Commercial Officer and Chief Financial Officer, to bolster its leadership team. These changes aim to support the company's strategic growth initiatives and operational efficiency.

Insider Trading Activity

Over the past two years, insider transactions show a net sale of shares. While some insiders have made significant purchases, others, including founders and key executives, have divested portions of their holdings.

Market Capitalization Trends

The company's market valuation has seen considerable volatility, with a substantial decline in 2024 followed by a recent rebound. This fluctuation reflects market sentiment and the company's performance within the biotechnology sector.

Institutional Ownership Growth

Institutional investors have increased their stake in the company, with a significant number of firms now holding substantial shareholdings. This trend suggests growing confidence from the broader investment community in the company's long-term prospects, as detailed in a Brief History of 10X Genomics.

10X Genomics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔